XOMA Royalty Swings to Profit on Revenue Surge, Acquisition Gains

TL;DR

**XOMAP is a BUY; strong revenue growth and strategic acquisitions are driving a clear path to profitability, making it a solid bet for long-term gains.**

AI Summary

XOMA Royalty Corp. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $25.609 million compared to a net loss of $9.853 million in the same period of 2024. Total income and revenues surged to $38.392 million, a substantial increase from $19.773 million year-over-year, driven by higher income from purchased receivables under both the EIR method ($19.039 million vs. $9.985 million) and the cost recovery method ($9.125 million vs. $1.910 million). The company also recognized a notable gain on acquisitions of $18.004 million for the nine months ended September 30, 2025, contributing significantly to profitability, contrasting with a $19.316 million gain in the prior year. Operating expenses decreased to $29.190 million from $52.496 million, primarily due to the absence of credit losses on purchased receivables in 2025, which were $23.000 million in 2024. Cash and cash equivalents, however, decreased to $45.189 million as of September 30, 2025, from $101.654 million at December 31, 2024, while total assets grew to $263.151 million from $221.277 million. Long-term debt also saw a slight reduction to $94.382 million from $106.875 million.

Why It Matters

XOMA Royalty's shift from a net loss to a significant net income demonstrates improved operational efficiency and successful strategic acquisitions, which is crucial for investor confidence. The substantial increase in revenue from purchased receivables indicates a robust pipeline of royalty streams, potentially signaling sustained growth. For employees, this financial health could mean greater job security and potential for growth within a more stable company. Customers of the underlying pharmaceutical products benefit from continued development and commercialization, supported by XOMA's royalty investments. In the broader market, XOMA's performance highlights the increasing viability and attractiveness of the life sciences royalty financing model, potentially drawing more capital into the sector and intensifying competition among royalty aggregators.

Risk Assessment

Risk Level: medium — While XOMA Royalty Corp. reported strong net income and revenue growth, its cash and cash equivalents significantly decreased from $101.654 million to $45.189 million, indicating substantial cash outflow. Additionally, the company's business model relies heavily on the success of underlying pharmaceutical products, as evidenced by the $23.000 million in credit losses on purchased receivables in 2024, a risk that could recur if product performance falters.

Analyst Insight

Investors should consider XOMAP as a potential long-term holding, given the strong net income turnaround and revenue growth. However, closely monitor cash flow statements in future filings to ensure the company maintains adequate liquidity for its acquisition-heavy strategy and to mitigate risks associated with its royalty-dependent revenue model.

Financial Highlights

debt To Equity

0.61

revenue

$38.392M

operating Margin

N/A

total Assets

$263.151M

total Debt

$108.727M

net Income

$25.609M

eps

N/A

gross Margin

N/A

cash Position

$45.189M

revenue Growth

+94.5%

Revenue Breakdown

Key Numbers

• $25.609M — Net Income (Swung from a $9.853M loss in 2024 to a profit in 2025, indicating a significant financial turnaround.)
• $38.392M — Total Income and Revenues (Increased by 94% from $19.773M in 2024, driven by strong royalty stream performance.)
• $19.039M — Income from EIR method receivables (Increased from $9.985M in 2024, showing growth in core royalty assets.)
• $9.125M — Income from cost recovery method receivables (Increased from $1.910M in 2024, reflecting successful recovery on certain royalty assets.)
• $18.004M — Gains on Acquisitions (A key contributor to profitability in 2025, demonstrating successful strategic asset integration.)
• $23.000M — Credit Losses on Purchased Receivables (2024) (Absence of these losses in 2025 significantly reduced operating expenses, highlighting improved asset quality or management.)
• $45.189M — Cash and Cash Equivalents (Decreased from $101.654M at year-end 2024, indicating significant cash utilization, likely for acquisitions or operations.)
• $263.151M — Total Assets (Increased from $221.277M at year-end 2024, reflecting growth in the company's asset base, including intangible assets.)
• $94.382M — Long-term Debt (Decreased from $106.875M at year-end 2024, showing a reduction in long-term financial obligations.)
• 12,383,103 — Common Stock Shares Outstanding (As of November 7, 2025, indicating the current dilution level for common stockholders.)

Key Players & Entities

• XOMA Royalty Corporation (company) — Registrant and primary subject of the 10-Q filing
• $25.609 million (dollar_amount) — Net income for the nine months ended September 30, 2025
• $9.853 million (dollar_amount) — Net loss for the nine months ended September 30, 2024
• $38.392 million (dollar_amount) — Total income and revenues for the nine months ended September 30, 2025
• $19.773 million (dollar_amount) — Total income and revenues for the nine months ended September 30, 2024
• $18.004 million (dollar_amount) — Gains on acquisitions for the nine months ended September 30, 2025
• $23.000 million (dollar_amount) — Credit losses on purchased receivables for the nine months ended September 30, 2024
• $45.189 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $101.654 million (dollar_amount) — Cash and cash equivalents as of December 31, 2024
• SEC (regulator) — U.S. Securities and Exchange Commission

FAQ

Risk Factors

• Credit Risk on Purchased Receivables [medium — financial]: While credit losses on purchased receivables were $23.000M in 2024 and absent in 2025, the company's reliance on these receivables introduces inherent credit risk. Future economic downturns or underperformance of underlying assets could lead to significant losses.
• Dependence on Royalty Asset Performance [high — market]: The company's revenue is heavily dependent on the performance of its acquired royalty and commercial payment receivables. Any decline in the underlying drug sales or commercial success of the associated products could materially impact income.
• Changes in Healthcare Regulations [medium — regulatory]: As a royalty company in the pharmaceutical sector, XOMA is indirectly exposed to changes in healthcare regulations, drug pricing policies, and patent laws. Adverse regulatory changes could impact the commercial viability of the underlying assets and thus XOMA's revenue.
• Integration of Acquisitions [medium — operational]: The company recognized a $18.004M gain on acquisitions in 2025, indicating active M&A strategy. However, the successful integration and ongoing management of acquired royalty streams are critical for realizing their full value and avoiding operational disruptions.
• Cash Position and Liquidity [medium — financial]: Cash and cash equivalents decreased from $101.654M at year-end 2024 to $45.189M as of September 30, 2025. While total assets grew, this significant cash utilization suggests potential investments or operational needs that require careful liquidity management.

Industry Context

XOMA operates in the specialized niche of acquiring royalty and commercial payment receivables, primarily within the pharmaceutical and biotechnology sectors. This industry is characterized by long product development cycles, significant R&D investment, and reliance on intellectual property. Key trends include consolidation among pharmaceutical companies, increasing focus on externalizing non-core assets, and evolving reimbursement and pricing pressures.

Regulatory Implications

As a company whose revenue is tied to pharmaceutical products, XOMA is indirectly subject to the stringent regulatory environment of the healthcare industry. Changes in drug approval processes, pricing regulations, and patent protection laws can significantly impact the value and revenue-generating potential of its acquired assets.

What Investors Should Do

1. Monitor the performance of key royalty streams: Investors should closely track the sales and commercial success of the underlying pharmaceutical products that generate XOMA's royalty income, as this is the primary driver of revenue and profitability.
2. Assess acquisition strategy and integration: Evaluate the company's ongoing acquisition activity, focusing on the strategic rationale, valuation, and successful integration of new royalty assets to ensure continued growth and value creation.
3. Analyze cash flow and liquidity: Given the significant decrease in cash and cash equivalents, investors should monitor the company's cash generation from operations and its ability to fund future investments and debt obligations.
4. Understand the impact of accounting methods: Pay attention to the revenue recognition under the EIR and cost recovery methods, as these significantly influence reported income and can be complex to analyze.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 financial results — Demonstrates a significant turnaround with net income of $25.609M and substantial revenue growth, driven by improved performance of royalty receivables.
• 2024-09-30: Nine months ended September 30, 2024 financial results — Reported a net loss of $9.853M and $23.000M in credit losses on purchased receivables, highlighting the contrast with 2025 performance.
• 2025-12-31: Year-end 2024 financial position — Provided the comparative balance sheet figures, showing $101.654M in cash and $221.277M in total assets.

Glossary

EIR method

Effective Interest Rate method, a way to account for revenue from purchased receivables that recognizes income over the life of the receivable based on a constant rate of return. (A primary driver of revenue growth for XOMA, with income increasing to $19.039M in 2025.)

Cost recovery method

A method of accounting where revenue is recognized only when the costs incurred are recovered, often used for receivables where there is uncertainty about full recovery. (Showed significant growth in income to $9.125M in 2025, indicating improved recovery on these assets.)

Gain on acquisitions

A profit recognized when the fair value of acquired assets exceeds the purchase price, or when a business combination results in a bargain purchase. (Contributed $18.004M to profitability in 2025, highlighting the company's strategic M&A activity.)

Credit losses on purchased receivables

Losses recognized when borrowers fail to repay amounts owed on receivables that the company has purchased. (The absence of these losses ($23.000M in 2024) significantly improved operating expenses and profitability in 2025.)

Contingent consideration

Future payments or obligations that depend on the occurrence of certain future events or conditions, often related to acquisitions. (Appears as a liability on the balance sheet, with a current portion of $1.976M and long-term portion of $4.807M in 2025.)

Intangible assets

Non-physical assets that have value, such as patents, copyrights, trademarks, and goodwill, often arising from acquisitions. (Increased significantly to $44.556M in 2025 from $25.909M in 2024, reflecting the value of acquired royalty streams.)

Year-Over-Year Comparison

XOMA Royalty Corp. has demonstrated a remarkable financial turnaround compared to the prior year. Total income and revenues more than doubled, surging by 94.5% from $19.773 million to $38.392 million for the nine months ended September 30, 2025. This growth, coupled with the absence of significant credit losses that impacted 2024, led to a substantial swing from a net loss of $9.853 million to a net income of $25.609 million. Operating expenses decreased significantly due to the elimination of $23.000 million in credit losses from the prior year, while total assets grew, indicating expansion of the company's asset base.

Key Financial Figures

• $0.0075 — ge on which registered: Common Stock, $0.0075 par value XOMA The Nasdaq Global Ma
• $0.05 — ve Perpetual Preferred Stock, par value $0.05 XOMAP The Nasdaq Global Market De

Filing Documents

• xoma-20250930x10q.htm (10-Q) — 3655KB
• xoma-20250930xex31d1.htm (EX-31.1) — 14KB
• xoma-20250930xex31d2.htm (EX-31.2) — 14KB
• xoma-20250930xex32d1.htm (EX-32.1) — 8KB
• 0001104659-25-109782.txt ( ) — 16703KB
• xoma-20250930.xsd (EX-101.SCH) — 126KB
• xoma-20250930_cal.xml (EX-101.CAL) — 110KB
• xoma-20250930_def.xml (EX-101.DEF) — 633KB
• xoma-20250930_lab.xml (EX-101.LAB) — 916KB
• xoma-20250930_pre.xml (EX-101.PRE) — 868KB
• xoma-20250930x10q_htm.xml (XML) — 3250KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 59 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 70 Item 4.

Controls and Procedures

Controls and Procedures 70 PART II OTHER INFORMATION 71 Item 1.

Legal Proceedings

Legal Proceedings 71 Item 1A.

Risk Factors

Risk Factors 71 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72 Item 3. Defaults Upon Senior Securities 73 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 74

Signatures

Signatures 76 2 Table of Contents GLOSSARY OF TERMS AND ABBREVIATIONS Abbreviations Definition 2010 Plan The Company's 2010 Long Term Incentive and Stock Award Plan, as amended 2018 Common Stock ATM Agreement At The Market Issuance Sales Agreement with HCW dated December 18, 2018 2021 Series B Preferred Stock ATM Agreement At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021 2025 Common Stock ATM Agreement At the Market Issuance Sales Agreement with Leerink dated October 3, 2025 2025 Series B Preferred Stock ATM Agreement At The Market Issuance Sales Agreement with HCW dated October 3, 2025 AAA Assignment and Assumption Agreement Affitech Affitech Research AS Affitech CPPA The Company's Commercial Payment Purchase Agreement with Affitech dated October 6, 2021 Aptevo Aptevo Therapeutics Inc. Aptevo CPPA The Company's Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as "Aptevo Commercial Payment Purchase Agreement" or "Aptevo CPPA" Alexion Alexion Pharmaceuticals Alexion License Agreement Exclusive License Agreement between the Company and Alexion (formerly Amolyt Pharma SAS, "Amolyt") dated December 19, 2024 ASC Accounting Standards Codification ASC 250 ASC Topic 250, Accounting Changes and Error Corrections ASC 310 ASC Topic 310, Receivables ASC 450 ASC Topic 450, Contingencies ASC 606 ASC Topic 606, Revenue from Contracts with Customers ASC 805 ASC Topic 805, Business Combinations ASC 815 ASC Topic 815, Derivatives and Hedging ASC 835-30 ASC Subtopic 835-30, Interest – Imputation of Interest ASC 842 ASC Topic 842, Leases ASU Accounting Standards Update Bayer License Agreement Out-license agreement to Bayer HealthCare LLC from Dar dated January 10, 2020, related to the development and commercialization of OVAPRENE BioInvent BioInvent International AB BioInvent License Agreement Cross-Licensing Agreement between the Company and BioInvent dated Nov

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS XOMA ROYALTY CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except share and per share amounts) September 30, December 31, 2025 2024 ASSETS Current assets: Cash and cash equivalents $ 45,189 $ 101,654 Short-term restricted cash 45,288 1,330 Investment in equity securities 1,521 3,529 Trade and other receivables, net 3,573 1,839 Short-term royalty and commercial payment receivables under the EIR method 13,269 14,763 Short-term royalty and commercial payment receivables under the cost recovery method 900 413 Prepaid expenses and other current assets 967 2,076 Total current assets 110,707 125,604 Long-term restricted cash 40,076 3,432 Property and equipment, net 24 32 Operating lease right-of-use assets 272 319 Long-term royalty and commercial payment receivables under the EIR method 4,678 4,970 Long-term royalty and commercial payment receivables under the cost recovery method 57,864 55,936 Exarafenib milestone asset (Note 6) 3,500 3,214 Investment in warrants 595 — Intangible assets, net 44,556 25,909 Other assets - long term 879 1,861 Total assets $ 263,151 $ 221,277 LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,654 $ 1,053 Accrued and other liabilities 4,134 5,752 Contingent consideration under RPAs, AAAs, and CPPAs — 3,000 Operating lease liabilities 2,508 446 Unearned revenue recognized under units-of-revenue method 1,320 1,361 Preferred stock dividend accrual 1,368 1,368 Current portion of long-term debt 14,345 11,394 Contingent value rights liabilities - current portion 1,976 — Total current liabilities 28,305 24,374 Unearned revenue recognized under units-of-revenue method – long-term 3,473 4,410 Exarafenib milestone c

View Full Filing

View this 10-Q filing on SEC EDGAR